Raymond James reiterates Tvardi Therapeutics stock rating on HCC data

Raymond James reiterated an Outperform rating and $10.00 price target for Tvardi Therapeutics (TVRD) after Q3 2026 earnings, citing encouraging data for TTI-101 in HCC and TTI-109's tolerability. The stock is down 73% YTD but appears undervalued, with upward earnings revisions. The HCC readout is delayed to Q1 2027. Other analysts also initiated coverage with buy ratings and price targets ranging from $8.00 to $14.00.

Original reporting
Published Nov 16, 2026, 12:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TVRD
Bullish
medium confidence
Mentioned
$TVRD
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TVRDBullishLow
01

Why it matters

The reiteration of an Outperform rating and a $10 target may attract short‑term buying interest, but the core fundamentals have not changed.

02

Market read

A modest analyst upgrade for a micro‑cap biotech; limited trading relevance beyond the stock itself.

03

What to watch

Financing risk for TTI‑109 and the need for additional capital could constrain upside.

Relevance 4/10Novelty 2/10Timing: post‑earnings day

Background

The article is an analyst rating update that repeats data from Tvardi's recent earnings release and trial updates.

Company-level read

Ticker impact

$TVRDBullishMedium confidence
Context

Raymond James reiterated an Outperform rating and $10 price target for Tvardi Therapeutics after its Q3 2026 earnings, citing encouraging trial data.

Expected impact

likely upward pressure as investors price in the higher target and trial optimism

Evidence & confidence

The rating and target are new analyst actions, but the underlying earnings and trial data were already public, limiting impact.

Market effects

Minimal; reinforces positive sentiment in the biotech/oncology space.

US biotech sector may see slight uptick.

Limited to investors tracking small‑cap biotech stocks.

Counterpoint

The stock remains highly volatile and heavily discounted; the upgrade may be premature.

Key entities

  • Raymond James

    Equity research firm providing the rating and price target.

  • Tvardi Therapeutics Inc

    Biotech firm developing STAT3 inhibitors for HCC and ulcerative colitis.

Related articles

$TVRDMed

Tvardi Therapeutics Reports Q3 2026 Net Loss of $6.1 Million

Tvardi Therapeutics reported a Q3 2026 net loss of $6.1M, up from $5.5M a year earlier. R&D expenses rose to $4.5M, while G&A expenses fell to $1.9M. The company had $22.3M in cash and expects funds to last into Q3 2027. Tvardi is preparing to advance TTI-109 into clinical trials for ulcerative colitis and expects Phase 1b/2 REVERT LIVER CANCER study results in early Q1 2027.

$TVRDMed

Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update HOUSTON, TX – November 13, 2026 – Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of

$TVRDMed

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immu

$TVRDMedAI 8/10

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

Tvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 results for its oral STAT3 inhibitor TTI-109. The company said TTI-109 rapidly converts to TTI-101, shows dose-proportional pharmacokinetics with exposures above the STAT3 IC50, and reduced STAT3-driven immune cell populations by up to 60% in exploratory analyses. It also cited shorter diarrhea duration vs TTI-101. TVRD shares rose sharply on the news.

$TVRDMed

Tvardi's TTI-109 Shows Improved Tolerability And Target Engagement In Phase 1 Study

Tvardi Therapeutics (TVRD) reported Phase 1 results for TTI-109, a phosphate prodrug of TTI-101. The drug converted rapidly and showed plasma exposure similar to TTI-101 at equivalent doses, with repeat dosing maintaining levels above the STAT3 inhibitory threshold for 21 days. Exploratory data showed up to 60% reductions in STAT3-driven immune cells and shorter diarrhea duration vs TTI-101. Phase 2 is planned pending funding.